

# MODUFOLIN®, A DRUG WITH THE POTENTIAL TO REPLACE ALL FOLATE-BASED DRUGS

The company's goal is to increase the efficacy and reduce the side effects of cytotoxics to improve the outlook for the majority of cancer patients undergoing chemotherapy treatments with 5-FU and HDMTX.

## SALSS CONTACT

Anders Rabbe  
CEO

anders.rabbe@isofolmedical.com  
+46 70 764 65 00

Isofol Medical AB  
Biotech Center  
Arvid Wallgrens Backe 20  
SE-413 46 Gothenburg, Sweden

www.isofol.se



# ISOFOL

ISOFOL MEDICAL AB | FIRST NORTH PREMIER: ISOFOL

Founded in 2008, Isofol Medical is a clinical-stage oncology company developing Modufolin®, a drug with the potential to replace all folate-based drugs, commonly used to enhance effectiveness or as a chemoprotectant in cancer treatment.

## OUR PRODUCTS & SERVICES

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer-related death with ~1.35 million people diagnosed annually worldwide. In the US, Western Europe and Japan, an estimated 550,000 patients are diagnosed with CRC annually, of whom about 365,000 receive a standard-of-care regimen that includes 5-FU and the folate leucovorin or levoleucovorin as a rescue treatment.

A high unmet need exists because current folate-based therapies are prodrugs that require several conversion steps to produce the active metabolite, and a majority of patients are unable to fully activate and transport these to the site of action.

Our clinical lead candidate, Modufolin®'s API is the key downstream metabolite of leucovorin and levoleucovorin, with expected efficacy independent of a patient's genetic capacity to activate folates used during treatment.

Modufolin® is under evaluation in two phase II studies together with (i) 5-FU for metastatic CRC; and (ii) after high-dose methotrexate treatment (HDMTX) in osteosarcoma.

Isofol holds an exclusive license for commercialising Modufolin® globally for cancer treatment, with access to the unique patented production process and the production capabilities of Merck KGaA.

## WHAT MAKES US UNIQUE

By purifying the key active metabolite of all the marketed folate-based prodrugs, Isofol has created a product that does not require metabolic activation to exert its action. Against this background, Modufolin® may be beneficial regardless of the patient's genetic ability to activate folates and thus holds the potential to replace the folates used in cancer treatment today.

## WHY YOU SHOULD MEET US

Isofol's has a large and clearly defined market opportunity with favourable route to market. In 2016, the FDA (IND cleared 2017) and EMA supported Isofol's clinical development plan for Modufolin in CRC allowing Isofol to proceed directly to a pivotal trial.

## KEY TEAM

Anders Rabbe

- CEO
- Joined Isofol Medical in 2010
- Broad financial and entrepreneurial background and has successfully been structuring and developing new ventures in various industries.
- CEO, CFO and board member in both private and listed companies

Jan-Eric Österlund

- Chairman
- Joined Isofol Medical in 2012
- Heavily involved in industrial life science development during the last thirty years in both private and listed companies
- Extensive experience as director and chairman in publicly listed companies quoted on stock exchanges in USA, Canada, Switzerland and Sweden

